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The aim was to assess outcome in a population-based cohort of adolescents with Hodgkin’s lymphoma (HL) diagnosed in the UK’s
northern region over a 10-year period. Among a population of 3.09 million, 55 of 676 patients (8%) diagnosed with HL were aged
13–19. Seven had nodular lymphocyte-predominant HL, 48 classical HL (cHL). Of the latter, 36 were X16 years. Application of the
Scottish and Newcastle Lymphoma Group (SNLG) prognostic index meant 21 patients were considered high risk (index X0.5).
They received PVACEBOP multi-agent chemotherapy as primary therapy. Standard risk patients (SNLG index o0.5) were treated
with standard ChlVPP or ABVD chemotherapy7radiotherapy. Scottish and Newcastle Lymphoma Group indexing is not valid for
patients under 16. Twelve patients therefore received UKCCSG protocols (n¼8), ABVD plus radiotherapy (n¼2), or PVACEBOP
(n¼2). Forty-six patients with cHL (96%) achieved complete remission. Seven patients relapsed but all entered complete remission
after salvage therapy. Five patients died: three of HL, one in an accident and one of disseminated varicella complicating cystic fibrosis.
Five- and 10-year overall survival was 93 and 86%, respectively; disease-specific survival was 95 and 92%. The data suggest that older
adolescents with high-risk HL require intensive protocols as primary therapy to secure optimal outcome.
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Hodgkin’s lymphoma (HL) is a rare malignancy, with an incidence
of approximately 2.4 per 100000 per annum in developed
countries. In these countries, the incidence of the disease is very
low in young children, peaks in young adults, wanes in middle age
then gradually increases again over the later decades (Kennedy
et al, 1985; Armstrong et al, 1994). During the teenage years there
is a steep rise in the incidence of HL, culminating in the peak
incidence described in the third decade. There is increasing
circumstantial evidence that HL in young children may be the
result of a different pathological process to that occurring in young
adults.
One potentially significant observation is that HL in young
children is more clearly Epstein–Barr virus (EBV) associated than
in young adults. This may be important as there is increasing
evidence to suggest that the EBV status of tumour cells in HL has an
impact on prognosis. This effect may, however, be age dependent
(Jarrett et al, 2005; Keegan et al, 2005), although these observations
have not been replicated in all studies (Jarrett et al,2 0 0 5 ) .
Differences in histological subtype of HL in different age cohorts
may also be important. While in children, as in adults, the nodular
sclerosing (NS) subtype predominates, up to 30% may have mixed
cellularity (MC) disease. Among 17–20 year olds, however, the
incidence of MC disease is lower, affecting as few as 4% of
individuals in some studies.
Thus, it could be argued that adolescents as a group are
susceptible to both young adult-type and childhood-type HL, or
alternatively, that they may actually represent a unique cohort with
respect to the epidemiology, pathophysiology and potentially
prognosis of HL (Windebank, 2005).
In addition to the heterogeneous biological features of HL
presenting during the teenage years, it is pertinent to consider
the treatments and modes of treatment delivery to this group of
patients in the UK. The multidisciplinary team responsible for the
management of teenagers with HL varies and is dependent upon
local healthcare configurations. In many regions, patients aged
416 years are treated by adult haematologists or oncologists at
local hospitals, while those aged o16 years are managed by
paediatric oncology teams, generally at regional centres. More
recently, in some areas, patients are being treated on designated
teenage cancer units either by paediatric or adult teams. It is
unsurprising, therefore, that there are considerable variations in
the therapeutic regimens used in the management of these
patients; while some patients are treated using regimens primarily
designed for children (Jenkin et al, 1982; Ekert et al, 1988; Hudson
et al, 1993; Hunger et al, 1994; Shankar et al, 1997, 1998; Weiner
et al, 1997; Hutchinson et al, 1998; Schellong et al, 1999;
Landmann-Parker et al, 2000), others are managed using adult-
type approaches (Proctor et al, 1991; Yung et al, 2004).
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sSince 1991, patients aged 13–19 years and all adults diagnosed
with HL in the Northern Region of England, have been
prospectively managed using a risk-adapted treatment approach.
The Scotland and Newcastle Lymphoma Group (SNLG) prognostic
index (Figure 1A), proven to be of value in identifying high-risk
patients 415years old (Proctor et al, 1991), has been used to
determine whether patients would benefit from intensified
treatment. For those too young for valid use of the SNLG index,
poor risk status was assigned to those with high-stage and very
bulky or extensive extra-nodal disease – factors later confirmed to
be of significance by Smith et al, 2003 (Figure 1B). Although
patients were managed by a mixture of adult physicians and
paediatricians, the overall therapeutic strategy was consistent, with
the use of a common intensified protocol for the poor risk patients
identified either clinically or by the index. We present the results
of this treatment strategy.
PATIENTS AND METHODS
The Northern Region Lymphoma Group (NRLG) collected data
prospectively on all patients diagnosed with HL in the Northern
region of England, as previously described (Taylor et al, 1998;
Proctor et al, 2002). In addition, the Northern Region Young
Person’s Malignancy Registry (NRYPMR) collects data at pre-
sentation from all patients, aged p25 years diagnosed with a
malignant disease in the same geographical area (Cotterill et al,
2000). Patients were included in the present study if they presented
between 1 January 1991 and 31 December 2000 with histologically
confirmed, newly diagnosed HL, were aged 13–19 years (inclusive)
at diagnosis and were normally resident in the area at the time of
diagnosis. Histological material from all patients was centrally
reviewed prior to patient inclusion on the register as previously
described (Taylor et al, 1998).
Registration and follow-up
The following data were collected from each patient at the time of
registration: age, sex, histological subtype, full blood count, clinical
stage at presentation, presence or absence of bulk disease, presence
or absence of B-symptoms and first-line treatment modality. Level
of haemoglobin, absolute lymphocyte count, age, stage and bulk
disease assessment were required to calculate the SNLG index
(Proctor et al, 1991).
Follow-up data regarding attainment of remission, relapse,
requirement for second-line and subsequent therapy, date of death
and cause of death were obtained from treating physicians or case-
note review. Follow-up was to June 2005, or the date that the
patient was last known to be alive. Data collection and analysis
were undertaken with approval of the local ethical committee.
Treatment strategy
Patients aged 16–19 years were managed using a risk-adapted
strategy based on the SNLG prognostic index (Proctor et al, 1991).
High-risk patients Patients identified as high risk were eligible for
the SNLG-HD III trial protocol (Proctor et al, 2002), which
involved treatment with three consecutive 28-day cycles of an
eight-drug regimen (PVACEBOP: procarbazine, vinblastine, dox-
To calculate the index the patient’s age, clinical stage, absolute lymphocyte count, haemoglobin and bulk disease are required.
The index = 1.5858 – 0.0363 age+ 0.0005 age2
+ 0.0683 CS– 0.086 LC – 0.0587 Hb 
+ additional factor if bulk diseaseis present* 
Age is entered as an absolute figure in the equation
Clinical stage entered according to the key (Ann Arbor classification)
IA, IIA, IIIA     = 1 
IB, IIB = 2 
IIIB = 3 
IV = 4 
Absolute lymphocyte count is entered as a score
   = 1 
1.0–1.5×109 l–1 = 2
1.5–2.0×109 l–1 = 3 
>2.0×109 l–1 = 4 
Haemoglobin (Hb) in g dl–1 is entered as an absolute figure in equation 
*Bulk disease (a single node of  5 cm) or 30% of intrathoracic ratio add to index factor of 0.3
A total index score of 0.5 was the criteria for regarding patient as poor risk. 
 There is an on-line programme for calculation of the index at www.shieldstudy.co.uk
Factors in index accrue one point if present 1) Male sex
2) Clinical Stages 2B, 3B and 4  
3) Bulky mediastinum
4) Leukocytosis (WBC>13.5×103 mm–3
5) Anaemia (Hb<11 g)
Score 0–1 94% Disease-free survival (DFS)
   2 85% DFS 
   3 71% DFS 
4–5 49% DFS 
<1.0×109 l–1
A
B
Figure 1 (A) Scottish and Newcastle Lymphoma Group prognostic index for Hodgkin’s disease risk evaluation. (B) Prognostic index for childhood HD
risk evaluation (Smith et al, 2003).
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sorubicin, chlorambucil, etoposide, bleomycin, vincristine and
prednisolone; Table 1a). This was followed by involved-field
radiotherapy (RT) to residual masses or sites of original bulk
disease. Patients who gained a complete remission (CR) or good
partial remission (GPR) were then randomised between two
further cycles of PVACEBOP chemotherapy, or an autologous
haemopoietic stem cell transplant (HSCT) with etoposide and
melphalan preconditioning. High-risk patients who did not
consent to trial entry were allowed to have this chemotherapy
treatment off-study. Patients who relapsed or failed to remit were
treated with the salvage chemotherapy regimen IVE (ifosfamide,
etoposide (VP16) and epirubicin; Table 1b) and an autologous
HSCT. After PVACEBOP, mobilisation of stem cells can be
problematic if five courses have been used; so marrow harvest
will be required for autograft in such circumstances. Relapse after
PVACEPOP in this cohort was a rare event, so this was not a
practical problem.
Standard risk patients Patients with SNLG index o0.5 were
treated according to Northern Region Haematology Guidelines.
Early stage 1A and 2A patients received three courses of ChlVPP
(chlorambucil, vinblastine, procarbazine and prednisolone) or
ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) and
involved-field RT to sites of residual or initial bulk disease. Before
1994, extended-field RT was used alone as primary therapy.
Patients with higher-stage disease were treated with a minimum of
six courses of a four-drug schedule (ChlVPP or ABVD) and
involved-field RT.
Survival analysis
Since (NLPHL) is now regarded as a subtype of low-grade non-HL,
patients with this disease subtype have been analysed separately.
Overall survival (OS) was measured from the date of diagnosis
until the date of death. Disease-specific survival (DSS) was
measured after censoring the data for deaths unrelated to HL.
Event-free survival (EFS) was calculated from date of diagnosis to
failure to achieve remission, relapse, disease progression, death or
last follow-up.
Statistical analysis
Prism 4.0 (GRAPHPAD Software, San Diego, CA, USA) was used
for data analysis. Actuarial survival curves were compiled using
the Kaplan–Meier method (Kaplan and Meier, 1958). The log-rank
test was used to compare curves. Fisher’s exact test was used where
appropriate.
RESULTS
Patient characteristics
The former Northern Region of England has a population of 3.09
million. Over the 10 years of the study, 676 individuals presented
with histologically confirmed HL, of whom 55 (8%) were aged 13–
19 years at diagnosis. Of these, 48 patients (27 males, 21 females)
had classical HL (cHL) and seven (six males, one female) had
NLPHL. Median follow-up was 107 months (range 32–165) for
surviving patients. The clinical characteristics of the patients and
their outcomes during follow-up are shown in Tables 2a and b.
Classical HL (cHL)
Therapy and outcome Of the 48 patients in this group, 36 were
aged X16 years and were thus eligible for assessment using the
SNLG index, and 12 were aged o16 years; application of the SNLG
was not valid for this group. Outcomes by therapeutic modality
and age are shown in Figure 2. In all, 46 of 48 patients (96%)
achieved a remission after first-line therapy. Both primary
Table 1 PVACE BOP primary therapy for poor-risk cases (SNLG index
40.5)
(a) For high-risk Hodgkin’s disease
Day 1 Vinblastine (6mg m
 2 IV)
Day 1–3 Etoposide (IV 100mg m
 2 1 dose)
Oral (200mg m
 2 2 doses)
Days 1–14 Procarbazine (100mg m
 2 oral)
Days 1–14 Chlorambucil (6mg m
 2 oral)
Day 8 Adriamycin (25mg m
 2 IV)
Day 8 Vincristine (2mg IV)
Day 15 Bleomycin (6mg m
 2 IV)
Day 22 Bleomycin (6mg m
 2 IV)
Days 14–28 Prednisolone
(40mg daily oral)
Day 29 ¼Day 1 of next course
(b) Ifosphamide, VP16 and epirubicin (IVE) for relapsed or progressive Hodgkin’s
disease
VP16 200mg m
 2day
 1 as 2h infusion days 1–3
Epirubicin 50mg m
 2day
 1 IV day 1 (bolus)
Ifosphamide 3g m
 2 24h infusions days 1–3 with MESNA cover in 2.5l
dextrose saline
Abbreviations: IV, intravenously; IVE, ifosfamide, etoposide (VP16) and epirubicin;
PVACEBOP, procarbazine, vinblastine, doxorubicin, chlorambucil, etoposide, bleo-
mycin, vincristine and prednisolone; SNLG, Scottish and Newcastle Lymphoma
Group. Bleomycin omitted from cycles 4 and 5 if patients have had mantle/
mediastinal radiotherapy. A 100mg hydrocortisone IV administered with bleomycin.
Septrin (960mg), once daily, should be given throughout treatment on Mondays,
Wednesdays and Fridays. On day 1 of each cycle before ifosphamide is administered
a loading dose of 1.8gm
 2 of MESNA is given as an IV bolus. A final infusion of
MESNA 5.4g/m
2 (60% of total ifosphamide dose) will be given in 1.5l of dextrose
saline given over 12h. Three cycles, at 21-day intervals (neutrophils 41.5 10/9/l
and platelets 475 10/9/l) for a total of three courses. Patients receive phenytoin
(po 300mg) daily from days 1–5.
Table 2 Clinical features and outcome of the cohort
Gender Clinical stage Pathology SNLG index Smith index
Age M/F IA IB IIA IIB IIIA IIIB IVA IVB NS MC o0.5 X0.5 0/1 2 3 4/5 5 year DSS 5 year EFS
(a) Classical HL
o16 years 8/4 1 1 5 0 1 1 0 3 1 11 N/A N/A 4 3 4 1 100% 90%
X16 years 19/17 3 0 10 5 4 7 2 5 6 30 17 19 15 8 7 6 94% 79%
Gender Clinical stage SNLG index Smith index
M/F IA IB IIA IIB IIIA IIIB IVA IVB N/A o0.5 X0.5 0/1 2 3 4/5 5 year DSS 5 year EFS
(b) Lymphocyte-predominant HL
6/1 2 1 1 0 3 0 0 0 3 3 1 6 1 0 0 86% 67%
Abbreviations: DSS, disease-specific survival; EFS, event-free survival; HL, Hodgkin’s lymphoma; SNLG, Scottish and Newcastle Lymphoma Group.
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srefractory patients died of HL despite the use of high-dose salvage
chemotherapy. Seven patients relapsed after primary therapy,
three of these patients received radiotherapy alone as first-line
treatment. All patients re-entered remission after salvage che-
motherapy, but one subsequently died of HL. Two patients died of
causes unrelated to HL; one died in a road traffic accident (RTA)
and one (who also had cystic fibrosis) died of disseminated
varicella zoster infection 96 months after presentation while in first
CR. The 5-year and 10-year OS for this cohort was 93 and 86%,
respectively (Figure 3A). DSS rates were 95 and 92% (Figure 3B).
Twenty-one patients, regarded as having high-risk disease, were
treated using the PVACEBOP regimen (Table 1a). Of these, five
patients received chemotherapy alone, 16 received combined
therapy and four had an autologous transplantation in CR1 as
part of the SNLG-HD III trial. With respect to SNLG prognostic
index, 19 patients were aged X16 years and 17 of 19 had an SNLG
index X0.5, thus reaching the criteria for high-risk disease. Two
other patients with SNLG scores o0.5 were treated using the high-
risk protocol at the discretion of the treating physician. Both are
well in first CR and have experienced no late effects to date. Two
patients, aged 13 and 15 years, were also treated using this protocol
because of clinical poor risk profile with massive mediastinal
disease. There were two primary refractory patients, who
subsequently died of their disease, and one patient with a high-
SNLG index entered CR but relapsed on several occasions, and
died of progressive disease despite a reduced-intensity sibling
HSCT.
Nineteen patients were treated using four-drug regimens
(Figure 2). Combined chemotherapy and radiotherapy was used
as first-line therapy in 11 cases, and chemotherapy was used alone
in eight cases. All patients achieved CR. All patients treated in this
group were considered to have standard risk disease, with one
exception; a patient with a high-SNLG score was treated using this
protocol, as she could not tolerate oral medication. She relapsed 12
months after diagnosis and was salvaged with IVE followed by an
autologous HSCT. Another patient relapsed but was also alive in
CR2 after salvage chemotherapy and an autologous HSCT. This
patient’s primary therapy was considered suboptimal as she
became pregnant after two courses of chemotherapy and deferred
further treatment until the postnatal period.
Eight patients with localised disease were managed with
radiotherapy alone as first line-therapy (Figure 2). Five of these
A cHL aged <16 years
(n=12)
High risk
High risk
Low risk
(n=2) (n=10)
Four drug regimen  RT alone
(n=8) (n=2)
PVACEBOP CR CR 
(n=8) (n=2)
Alive in CR1 (n=1)
Died in RTA in CR1(n=1)
Alive in CR1 (n=8) Alive in CR1 (n=2) 
B
cHL aged16 years
(n=36)
Low risk
(n=19) (n=17)
RT alone   Four drug regimen RT alone   PVACEBOP 
(n=1) (n=1) (n=5) (n=2)
  PVACEBOP Four drug regimen
  (n=17) (n=10) 
Alive in CR3  Alive in CR2  Alive in CR1   Alive in CR1
(n=1) (n=1) (n=2) (n=2)
Died in CR1 
  (n=1) 
Alive in CR2 
(n=2)
Alive in CR1 (n=10) Alive in CR1 (n=9)
Alive in CR2 (n=3) Alive in CR2 (n=1)
Alive in CR3 (n=1) 
Died of HL (n=3)
Figure 2 (A) Classical HL aged o16 years. (B) Classical HL aged X16 years.
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spatients remained in CR1, three patients relapsed but had been
salvaged with chemotherapy and were alive in CR. One patient,
who also had cystic fibrosis, died 96 months after presentation of
disseminated varicella zoster infection.
Compliance with regional protocol As discussed, the SNLG index
can only be reliably applied to patients aged X16 years. With
regard to these patients, regional guidelines were followed in 32
out of 36 cases. Two low-indexed patients were treated on the
PVACEBOP protocol, one high-indexed patient received ABVD as
she could not tolerate oral medication and one high indexed
patient received radiotherapy alone.
Comparison of SNLG and Smith prognostic indices The Smith
Index (Figure 1B), a prognostic score for childhood HL, was
published in 2003 (Smith et al, 2003). It was therefore not available
during the period these patients were treated. Nevertheless there is
high concordance of Smith scores 3–5 as SNLG high-risk and
Smith scores o3 as low-risk SNLG . Overall, there is agreement in
risk allocation for 31 out of 36 patients. Five individuals were
scored as high risk using the SNLG index (Figure 1A) and low risk
using the Smith score. Of these patients, one received ABVD due to
intolerance of oral medication and relapsed but received successful
salvage therapy. Four patients received PVACEBOP-based therapy;
two patients relapsed, one of whom had subsequently died of
progressive disease. The Hasencleaver index could not be used in
this cohort, as the serum albumin estimations had been recorded
only in a minority of the cohort.
NLPHL
This group comprised seven patients, three aged o16 years and
four aged X16 years. Therapy comprised radiotherapy alone
(n¼3), ChlVPP/ABVDþradiotherapy (n¼2), ABVDþradio-
therapy (n¼1) and PVACEBOPþradiotherapy (n¼1). Remission
was achieved in 6/7 cases. The refractory patient was treated with
PVACEBOP, achieved a partial remission but relapsed 4 months
later with high-grade non-HL, and died of progressive disease 5
months after diagnosis. Two other patients relapsed but were
salvaged with chemotherapy and autologous HSCT.
DISCUSSION
Hodgkin’s lymphoma in patients aged over 15 years was a subject
of substantial research interest in the former Northern Region UK
from 1982 onwards. This led to the development of the SNLG
prognostic index in 1985, and although not published until 1991, it
was used prospectively to define risk status as ‘standard’ or ‘high’
from 1987 (Proctor et al, 1991). It became the defining element of
the SNLG-HD III randomised study for high-risk patients, which
ran from 1988 to 1998 (Proctor et al, 2002). As a result, adolescents
in the region who developed HL were prospectively assessed as
described above, hence the early emergence of the risk – related
strategy for the over 16 years cohort described here.
For patients with cHL, the 5-year and 10-year OS for this cohort
was 93 and 86%, respectively. Overall survival for patients with
early stage (stages IA, IIA) was 100 and 91%, respectively. These
results compare favourably with other published studies, which
have included adolescent patients (Table 3).
It should be borne in mind that, with the exception of the
present study and those of Yung et al (2004) and Foltz et al (2006),
all of the studies in Table 3 included younger children in addition
to adolescents. It is not clear whether the prognosis of HL is the
same in young children and teenagers; younger children have a
better outcome than adolescents in some (Weiner et al, 1991) but
not all studies (Schellong et al, 1999). In their study, specifically
investigating adolescents with HL, Yung et al (2004) demonstrated
a 5-year OS of 81% and EFS of 50% in a cohort of 210 patients.
These patients, aged 15–17 years, were diagnosed from 1970–1997
and were treated according to adult protocols. Based on these data,
the authors postulated that adolescents may be best treated using
paediatric rather than adult treatment protocols. Survival data
presented in our own study, using an adult risk-related approach,
are better than those reported by Yung and co-workers. There are
clearly several differences between the study of Yung and co-
workers and the present study. These need to be considered when
comparing results. The present study is population-based, the age
range of the patients treated is broader and the patients were
treated more recently than those described by Yung and co-
workers. There was, however, no difference in survival by decade
of treatment in the latter study. The present study describes the use
of a risk-adapted treatment strategy and has demonstrated
outcomes, which are comparable with those published by a
number of paediatric groups (Ekert et al, 1988; Shankar et al, 1998;
Schellong et al, 1999; Landmann-Parker et al, 2000; Smith et al,
2003; Oguz et al, 2005).
Recently Foltz et al (2006) have published the population
experience of the British Columbia Cancer Agency lymphoid
cancer database. The group included 259 individuals aged 16–
21yrs treated with adult therapy protocols. Overall survival and
progression-free survival at 10 years were 91 and 77%, respec-
tively. These survival data are similar to our own, with 10-year OS
and EFS of 86 and 78% respectively, and suggest that adolescents
can do well when managed using adult protocols.
The possible impact of the population-based nature of the data
collected in this series and that of Foltz and co-workers is worthy
of consideration. Among older patients with HL, it has been
repeatedly demonstrated that the survival data in population-
based studies are poorer than those from clinical trials (Kennedy
et al, 1985; Appleton et al, 1995; Clarke et al, 2001; Proctor et al,
2002; Jarrett et al, 2005). This effect is likely to be due, at least in
part, to the exclusion of frailer elderly individuals from clinical
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Figure 3 (A) Overall survival. (B) Disease-specific survival (censored for
deaths unrelated to HL).
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sTable 3 Published outcomes for adolescent patients with HL
Authors
Publication
year
Number of
patients
Ages
(years)
Median age
(years) Stages
NLPHL
included
Median F/U
(month) CR rate 5 year OS 5 year EFS Study type
Clarke et al 2001 5630 15–44 NS NS Yes 53 NS NS 5 year DFS 90% Retrospective, population based
Donaldson and
Link
1987 55 1.5–15 10 All Yes 90 93% 89% at 15 years 5 year RFS 90% Prospective, observational
Donaldson et al 2002 110 3–20 13 All Yes 67 100% 99% 93% Prospective, observational, focused on LR
disease
Ekert et al 1988 53 3–16 10 All Yes 45 96% 94% 92% Prospective observational
Foltz et al 2006 259 16–21 19 All Yes 102 97% 91% 10 year PFS 77% Prospective observational
Friedmann et al 2002 56 8–18 15 All (only HR I–II) Yes 108 94% 82% 68% Prospective, observational, focused on HR
disease
Hudson et al 1993 85 4–20 14 IIA–IVB Yes 49 98% 93% 5 year DFS 93% Prospective, observational, focused on HR
disease
Hudson et al 2004 159 2–19 15 All (only HR I–II) Yes 70 NS 93% 76% Prospective, observational, focused on HR
disease
Hunger et al 1994 57 o18 12 All Yes 80 100% 96% 93% Prospective, observational
Hutchinson
et al
1998 111 o21 NS III/IV only Yes 74 NS 87% at 4 years 82% at 4 years RCT, focused on HR disease
Jenkin et al 1982 110 o16 NS All Yes 70 NS 92% RFS 68% Prospective, observational
Jones et al Present paper
2007
55 13–19 16 All Yes 107 93% 91% NS Prospective, population-based
Landman-
Parker et al
2000 202 3–18 12 I/II only No 74 NS 98% 91% Prospective, observational, risk-adapted
approach
Nachman et al 2002 829 o21 NS All Yes NA 83% 95% at 3 years 87% at 3 years RCT for patients in CR after chemotherapy
Oguz et al 2005 65 2–15 7 All Yes 73 95% 96% 91% Prospective, observational
Schellong et al 1999 578 2–17 13 All Yes 61 NS 98% 91% Prospective, observational
Shanker et al 1998 54 2–19 10 All Yes 66 76% Stage I–III 93%
Stage IV 44%
Prospective, observational
Smith et al 2003 328 2–20 14 All Yes 59 NS 93% DFS at 5 years 83% Prospective, observational using risk-
adapted protocols
Weiner et al 1997 179 4–20 13 XIIB Yes NS 90% 92% 79% RCT focused on HR disease
Yung et al 2004 210 15–17 16 All Yes 199 76% 81% 50% Retrospective, observational
Abbreviations: CR, complete remission; DFS, disease-free survival; EFS, event-free survival; HL, Hodgkin’s lymphoma; HR, high risk; LR, low risk. NA, not available; NLPHL, nodular lymphocyte-predominant Hodgkin’s lymphoma; NS,
non-significant; OS, overall survival; RCT, randomised controlled trial.
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strials. It is not clear, however, whether a population-based
approach may have a different impact in adolescent patients. It
is conceivable that young patients with HL and poor prognostic
features may enter trials in preference to those with lower-risk
disease and indeed many clinical trials focus on those patients with
poorer-risk disease (Hudson et al, 1993, 2004; Hutchinson et al,
1998; Friedmann et al, 2002). This may be another explanation of
the differences between the present investigation and that of Yung
co-workers; most of the patients in the latter study were registered
at the time of recruitment to clinical trials.
While several studies (Jenkin et al, 1982; Shankar et al, 1998;
Schellong et al, 1999; Oguz et al, 2005; Foltz et al, 2006) stratified
patients to receive therapy based on stage of disease at
presentation, no group specifically took into account additional
prognostic factors such as those that comprise the SNLG index.
Given the population-based nature of our study and the age range
of patients included, we contend that the survival data presented in
this cohort, the small number of patients requiring salvage
therapy, and to date lack of secondary malignancy justifies our
risk-adapted approach. Using an alternative strategy, Landmann-
Parker et al (2000), stratified patients based on their response to an
initial four cycles of chemotherapy. This group studied only
patients with early stage disease; the results are similar to our own
for patients with IA and IIA disease.
Current and proposed trials are assessing the use of PET
scanning during therapy to inform the risk issue on an individual
patient during treatment. This approach seems to have much merit
as it allows standard or escalated therapy to be introduced
according to response. The additional value of such an approach is
that fertility might be better preserved in male patients using
ABVD alone. Certainly eight-drug schedules, such as PVACEBOP,
are associated with inevitable male sterility, although female
fertility in the under 40 years patients on SNLG-HD III (Proctor
et al, 2002) has been well preserved. We would argue that the new
study approaches should be linked to assessment of existing
prognostic indices to further assess their role in defining risk.
Nodular lymphocyte-predominant HL is now recognised as
being a form of low-grade B-cell non-HL rather than a variant of
cHL (Stoler et al, 1995; Harris et al, 2000). Several studies,
including the small cohort investigated in the present series, have
failed to demonstrate a survival difference between patients with
NLPHL and those with other forms of the disease (Proctor et al,
1991; Weiner et al, 1991; Hunger et al, 1994). It seems unlikely that
inclusion or exclusion of this small proportion of patients from the
studies outlined in Table 3 would have a significant impact on
overall results.
One of the other major considerations in the treatment of young
patients with HL is the risk of late adverse effects of treatment. In the
present study, follow-up is too short to allow an accurate assessment
of the late effects of this risk-adapted therapeutic approach, but the
results are generally encouraging; no secondary leukaemia or solid
tumours have been reported in this cohort to date.
CONCLUSION
This study demonstrates that a coordinated approach, involving
adult and paediatric physicians, and the use of a risk-adapted
treatment protocol are effective in the management of HL in
adolescents. Given the relative rarity of HL in adolescents, a
national population-based registry approach could provide valu-
able information with respect to best practice in addition to
providing a vehicle to promote recruitment into clinical trials.
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